STK-001 70mg achieves 80% median convulsive seizure reduction at 3 months in Dravet syndrome

Stoke Therapeutics, Inc.

70mg multiple-dose cohort (n=6): median convulsive seizure reduction 80% at 3 months, 89% at 6 months after last dose.
30mg and 45mg OLE data show durable seizure reductions and improvements in cognition/behavior per VABS-III and BRIEF-P.
Safety: generally well-tolerated in 74 patients; one SUSAR attributed to drug; no treatment-related discontinuations.
Additional Phase 1/2a end-of-study data and Phase 3 planning update expected in Q1 2024 and H1 2024 respectively.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.